Analysen von Graham Parry
06.12.17 | Novartis Underperform | Merrill Lynch & Co., Inc. | |
20.05.15 | GSK Underperform | Merrill Lynch & Co., Inc. | |
09.12.14 | GSK Underperform | Merrill Lynch & Co., Inc. |
06.12.17 | Novartis Underperform | Merrill Lynch & Co., Inc. | |
20.05.15 | GSK Underperform | Merrill Lynch & Co., Inc. | |
09.12.14 | GSK Underperform | Merrill Lynch & Co., Inc. |